View Older Stories View More Recent Stories

May 30, 2017 08:05AM Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology’s ASM Microbe 2017 Conference
May 16, 2017 07:05AM Matinas BioPharma Reports 2017 First Quarter Financial Results and Provides Corporate Update
Apr 24, 2017 07:00AM Matinas BioPharma Presents Positive Preclinical Data of Orally Available DNA Vaccines at the 27th Annual European Congress of Clinical Microbiology and Infectious Diseases
Apr 18, 2017 07:01AM Matinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance
Apr 3, 2017 07:06AM Matinas BioPharma Reports 2016 Financial Results and Provides Corporate Update
Mar 30, 2017 07:06AM Matinas BioPharma (MTNB) Appoints Eric Ende to its Board of Directors
Mar 30, 2017 07:05AM Matinas BioPharma Appoints Eric J. Ende, M.B.A, M.D. to its Board of Directors
Mar 29, 2017 07:05AM Matinas BioPharma to Host Fiscal Year 2016 Update Conference Call
Mar 28, 2017 07:35AM Matinas BioPharma to Ring NYSE Closing Bell on March 29th, 2017
Mar 27, 2017 07:43AM Matinas BioPharma (MTNB) Announces Topline Data from Phase 1 Study of MAT2501
Mar 27, 2017 07:35AM Matinas BioPharma Reports Positive Topline Data from Phase 1 Study of MAT2501
Mar 10, 2017 08:05AM Matinas BioPharma to Present at 29th Annual ROTH Conference
Mar 8, 2017 08:01AM Matinas BioPharma Announces Positive Preclinical Efficacy Results of MAT2501 in an In Vitro Model of Mycobacterium abscessus Infection
Mar 6, 2017 08:09AM Matinas BioPharma (MTNB), NIH/NIAID Initiate Open-Label Extension to Phase 2a Study of MAT2203 in CMCC
Mar 6, 2017 08:05AM Matinas BioPharma and NIH/NIAID Initiate Open-Label Extension to Phase 2a Study of MAT2203 in Chronic Mucocutaneous Candidiasis
Feb 27, 2017 08:30AM Matinas BioPharma Announces Trading on NYSE MKT to Commence March 2, 2017
Jan 26, 2017 07:00AM Matinas BioPharma Provides Business Outlook and Sets Corporate Milestones for 2017
Jan 23, 2017 07:05AM Matinas BioPharma to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
Jan 19, 2017 07:05AM Matinas BioPharma Successfully Completes Warrant Tender Offer – Raises $13.5 Million from Exercise of Warrants
Jan 6, 2017 07:35AM Matinas BioPharma to Present at Biotech Showcase™ 2017
Dec 8, 2016 07:05AM Matinas BioPharma Receives Contract Award from Cystic Fibrosis Foundation Therapeutics to Study MAT2501 for the Treatment of NTM-Infection in Pre-Clinical Models of CF
Dec 5, 2016 07:08AM Matinas BioPharma (MTNB) Begins Dosing in MAT2501 Phase 1
Dec 5, 2016 07:05AM Matinas BioPharma Commences Dosing in Phase 1 Study of Orally Administered Aminoglycoside Antibiotic MAT2501
Nov 21, 2016 07:05AM Matinas BioPharma Initiates Enrollment and Commences Patient Dosing in Phase 2 Study of MAT2203 for the Treatment of Vulvovaginal Candidiasis
Nov 15, 2016 07:05AM Matinas BioPharma Reports 2016 Third Quarter Financial Results and Provides Corporate Update
Nov 3, 2016 07:35AM Matinas BioPharma Researchers Among Rutgers University Recipients of 2016 Edison Patent Awards
Oct 26, 2016 07:35AM Matinas BioPharma Presents Preclinical Data of Orally Administered Encochleated Influenza Vaccine in Murine Model at IDWeek 2016
Oct 24, 2016 07:05AM Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
Oct 13, 2016 07:05AM Matinas BioPharma to Present at the 2nd Annual Dawson James Securities Growth Stock Conference
Sep 28, 2016 07:00AM Matinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203
Sep 13, 2016 07:05AM Matinas BioPharma Completes Private Placement of $8.0 Million
Sep 7, 2016 07:05AM Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Prophylaxis of Invasive Fungal Infections by U.S. FDA
Sep 6, 2016 07:05AM Matinas BioPharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13, 2016
Jul 13, 2016 07:00AM Matinas BioPharma Announces Presentation of Cryptococcal Meningitis Preclinical Data of MAT2203 at AIDS-Associated Mycosis Meeting 2016
Jun 22, 2016 07:05AM Matinas BioPharma Receives Issuance of Key U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
Jun 20, 2016 07:35AM Matinas BioPharma Presents Preclinical Data of MAT2501 at ASM Microbe/ICAAC 2016
Jun 8, 2016 07:00AM Matinas BioPharma Announces Acceptance of Abstract on Efficacy and Tolerability of Encochleated Ibuprofen in Rat Carrageenan-Induced Paw Inflammation Model for EULAR 2016
Mar 31, 2016 07:05AM Matinas BioPharma Reports 2015 Financial Results and Provides Business Update
Mar 10, 2016 07:35AM Matinas BioPharma to Present at the 28th Annual ROTH Conference
Mar 7, 2016 07:05AM Matinas BioPharma Granted U.S. Orphan Drug Designation for MAT2501 for Treatment of Non-Tuberculous Mycobacteria Infections
Feb 10, 2016 08:05AM Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
Feb 8, 2016 07:05AM Matinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study With MAT2203 - Oral Encochleated Amphotericin B
Feb 1, 2016 07:35AM Matinas BioPharma Receives FDA Clearance to Initiate Phase 1 Clinical Study of MAT2501 for the Treatment of Non-Tuberculous Mycobacterium Infections
Jan 5, 2016 07:01AM Matinas BioPharma to Present at Biotech Showcase™ on January 12, 2016
Jan 4, 2016 07:05AM Matinas BioPharma Files Investigational New Drug Application With U.S. FDA for Lead Antibacterial Development Candidate MAT2501
Dec 17, 2015 07:05AM Matinas BioPharma’s Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA
Dec 14, 2015 07:05AM Matinas BioPharma’s Lead Antibacterial Development Candidate MAT2501 Granted QIDP Designation by U.S. FDA
Nov 19, 2015 07:05AM Matinas BioPharma to Present at the 8th Annual LD Micro Main Event on December 3, 2015
Nov 10, 2015 07:35AM Matinas BioPharma Reports 2015 Third Quarter Financial Results and Provides Business Update
Oct 26, 2015 08:05AM Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Encochleated siRNA
View More Recent Stories View Older Stories